EQS-News: Positive judgment of the European Court of Justice strengthens the position of Redcare Pharmacy and its customers.
|
EQS-News: Redcare Pharmacy N.V.
/ Key word(s): Statement
Positive judgment of the European Court of Justice strengthens the position of Redcare Pharmacy and its customers. Sevenum, the Netherlands, 27 February 2025 – Redcare Pharmacy welcomes today's judgment of the European Court of Justice that advertising measures that promote the purchase of prescription medicines in the form of direct discounts or payments of an exact amount are allowed. This confirms Redcare Pharmacy’s long-standing position since the ECJ’s judgment in 2016 (C-148/15, Deutsche Parkinson Vereinigung) that it is entitled to grant bonuses on prescription orders to the benefit of its customers. “As Europe's leading customer-centric online pharmacy, we welcome this judgment, which offers us the opportunity to further optimise our customer offerings. We will carefully review the judgment,” Olaf Heinrich, CEO of Redcare Pharmacy, comments. Link to the ECJ press release, English and German version: https://curia.europa.eu/jcms/upload/docs/application/pdf/2025-02/cp250023en.pdf About Redcare Pharmacy. Founded in 2001, Redcare Pharmacy (formerly Shop Apotheke Europe) is now the leading online pharmacy in Europe and currently active in seven countries: Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland. The company is headquartered in Sevenum, NL in the heart of Europe, with further locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven. As the one-stop pharmacy of the future, Redcare Pharmacy offers around 12.5 million active customers a wide range of more than 150,000 products at fair prices. In addition to over-the-counter medicines, nutritional supplements, beauty and personal care products, and a wide selection of health-related items in all markets, the company also offers prescription drugs to customers in Germany, Switzerland and the Netherlands. Pharmaceutical safety is always the top priority. With pharmacy at its core, providing sound pharmaceutical advice is clearly at the center of Redcare's focus. The “Care” in the name stands for a wide range of services for all stages of life and health issues: from marketplaces to unique delivery options and medication management. Redcare Pharmacy N.V. has been listed on the Frankfurt Stock Exchange (Prime Standard) since 2016. As of June 19, 2023, the company is a member of the MDAX selection index.
27.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Redcare Pharmacy N.V. |
| Erik de Rodeweg 11-13 | |
| 5975 WD Sevenum | |
| Netherlands | |
| Phone: | 0800 - 200 800 300 |
| Fax: | 0800 - 90 70 90 20 |
| E-mail: | investors@redcare-pharmacy.com |
| Internet: | www.redcare-pharmacy.com |
| ISIN: | NL0012044747, DE000A19Y072 |
| WKN: | A2AR94, A19Y072 |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2092761 |
| End of News | EQS News Service |
|
|
2092761 27.02.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 701,01 | 968,06 | 1.060,32 | 1.204,35 | 1.798,76 | 2.370,58 | 3.000,00 | |
| EBITDA1,2 | -18,58 | 15,20 | -38,73 | -29,66 | 39,99 | 29,23 | 63,00 | |
| EBITDA-Margin3 | -2,65 | 1,57 | -3,65 | -2,46 | 2,22 | 1,23 | 2,10 | |
| EBIT1,4 | -33,45 | -0,87 | -65,70 | -69,17 | -17,30 | -38,99 | -8,00 | |
| EBIT-Margin5 | -4,77 | -0,09 | -6,20 | -5,74 | -0,96 | -1,65 | -0,27 | |
| Net Profit (Loss)1 | -36,27 | -16,77 | -74,19 | -77,65 | -11,61 | -46,36 | -19,00 | |
| Net-Margin6 | -5,17 | -1,73 | -7,00 | -6,45 | -0,65 | -1,96 | -0,63 | |
| Cashflow1,7 | -30,37 | 17,80 | 11,64 | -29,11 | 61,46 | 22,13 | 28,00 | |
| Earnings per share8 | -2,78 | -1,17 | -4,15 | -4,32 | -0,73 | -2,27 | -0,92 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Forvis Mazars
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Redcare Pharmacy | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A2AR94 | NL0012044747 | N.V. | 2.448,83 Mio € | 13.10.2016 | Kaufen | 9F3893WC+F5 |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 56,67 | 0,00 | 0,00 | -54,61 | 5,06 | 110,68 | 1,03 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 15.05.2025 | 06.05.2025 | 29.07.2025 | 28.10.2025 | 11.03.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -2,32% | -9,95% | -10,32% | -15,30% | +325,00% |
